Liquid Biopsy Market Size, Share, Emerging Factors, Trends, Segmentation and Forecast to 2035 #2

Date of Publication: May 27, 2025 Roots Analysis has published its latest report titled ‘‘Liquid Biopsy Market “, offering an in-depth overview of the global landscape. This study provides a historical perspective and a future outlook for the market, analyzing trends and growth patterns from 2025 to 2035. The report explores how the market size has evolved and identifies the major forces shaping its direction in the coming years.

The liquid biopsy market size is estimated to grow from USD 6.09 billion in 2024 to USD 29.8 billion by 2035, growing at a CAGR of 15.53% from 2024 to 2035. This projected growth is supported by steady expansion across multiple regions and consistent adoption across key crop types. The report refrains from speculative assumptions, offering fact-based analysis of market shifts and potential opportunities.

Source of information: - https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/279.html

The research includes a clear breakdown of business activities, competitive strategies, and investment initiatives. It outlines the position of top companies in ‘Liquid Biopsy and discusses their strategic moves in the global space. Their financial performance, product ranges, and operational footprints are presented to support understanding of the competitive structure within the ‘Liquid Biopsy Market.

Type of Circulating Biomarker

Cell Free DNA

Cell Free RNA

Circulating Tumor DNA

Extracellular Vesicles

Other Circulating Biomarkers

Type of Sample

Blood / Plasma

Other Samples

End User

Hospitals

Research Institutes

Others

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Key Companies Profiled

Amoy Diagnostics

ArcherDX

Biocartis

Cell Search

CellMax Life

Datar Cancer Genetics

DiaCarta, EONE-DIAGNOMICS

Exosome Diagnostics

GeneCast Biotechnology

Integrated DNA Technologies

Lucence

MDNA Life Sciences

Miltenyi Biotec

NeoGenomics

ONCODE Scientific

OncoDNA

QIAGEN

PANAGENE

Personal Genome Diagnostics

Predicin

ScreenCell

Tecan

Thermo Fisher Scientific

The geographical scope of the study covers Amoy Diagnostics, ArcherDX, Biocartis, Cell Search, CellMax Life , Datar Cancer Genetics, DiaCarta, EONE-DIAGNOMICS, Exosome Diagnostics, GeneCast Biotechnology, Integrated DNA Technologies, Lucence, MDNA Life Sciences, Miltenyi Biotec, NeoGenomics , ONCODE Scientific, OncoDNA, QIAGEN, PANAGENE, Personal Genome Diagnostics, Predicin, ScreenCell , Tecan, Thermo Fisher Scientific. Each region is examined with respect to current demand, accessibility of products, and regional developments. These geographic insights contribute to a deeper understanding of the global ‘Liquid Biopsy Market share and help identify performance differences between developed and emerging markets.

The report features profiles of key players operating in the ‘Liquid Biopsy sector, including Amoy Diagnostics, ArcherDX, Biocartis, Cell Search, CellMax Life , Datar Cancer Genetics, DiaCarta, EONE-DIAGNOMICS, Exosome Diagnostics, GeneCast Biotechnology, Integrated DNA Technologies, Lucence, MDNA Life Sciences, Miltenyi Biotec, NeoGenomics , ONCODE Scientific, OncoDNA, QIAGEN, PANAGENE , Personal Genome Diagnostics, Predicin, ScreenCell , Tecan, Thermo Fisher Scientific. These company profiles provide a snapshot of their business strategy, market presence, and major contributions to the ‘Liquid Biopsy Market.

The study further discusses market performance across various regions, product categories, and other segments. It presents a factual evaluation of the ‘Liquid Biopsy industry share and reviews the regulatory and operational dynamics influencing global adoption. The report emphasizes consistency and clarity in presenting the forecast model and expected market trajectory.

Readers are also presented with analysis on corporate strategies including mergers and acquisitions, regional partnerships, and joint ventures. These strategies are reviewed in the context of historical data and current execution trends, offering an informed overview of ‘Liquid Biopsy Market growth potential.

The report highlights the impact of external conditions such as pricing changes, investment flow, and emerging business models. It avoids speculation and focuses on available insights that can guide real-world business decisions. Coverage includes major areas of interest for companies exploring new opportunities in the market for ‘Liquid Biopsy.

Research Methodology
This study is backed by structured primary and secondary research methodologies. Roots Analysis used a range of reliable sources including company disclosures, government records, and expert interviews. The research framework supports accurate and transparent analysis, allowing businesses to derive actionable insights from the ‘Liquid Biopsy Market forecast.

For more information or to request a personalized version of this report, please contact our team at sales@rootsanalysis.com. We are happy to support your specific business objectives with customized research solutions.

Date of Publication: May 27, 2025 Roots Analysis has published its latest report titled ‘‘Liquid Biopsy Market “, offering an in-depth overview of the global landscape. This study provides a historical perspective and a future outlook for the market, analyzing trends and growth patterns from 2025 to 2035. The report explores how the market size has evolved and identifies the major forces shaping its direction in the coming years. The [liquid biopsy market](https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/279.html) size is estimated to grow from USD 6.09 billion in 2024 to USD 29.8 billion by 2035, growing at a CAGR of 15.53% from 2024 to 2035. This projected growth is supported by steady expansion across multiple regions and consistent adoption across key crop types. The report refrains from speculative assumptions, offering fact-based analysis of market shifts and potential opportunities. Source of information: - https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/279.html The research includes a clear breakdown of business activities, competitive strategies, and investment initiatives. It outlines the position of top companies in ‘Liquid Biopsy and discusses their strategic moves in the global space. Their financial performance, product ranges, and operational footprints are presented to support understanding of the competitive structure within the ‘Liquid Biopsy Market. Type of Circulating Biomarker Cell Free DNA Cell Free RNA Circulating Tumor DNA Extracellular Vesicles Other Circulating Biomarkers Type of Sample Blood / Plasma Other Samples End User Hospitals Research Institutes Others Key Geographical Regions North America Europe Asia-Pacific Rest of the World Key Companies Profiled Amoy Diagnostics ArcherDX Biocartis Cell Search CellMax Life Datar Cancer Genetics DiaCarta, EONE-DIAGNOMICS Exosome Diagnostics GeneCast Biotechnology Integrated DNA Technologies Lucence MDNA Life Sciences Miltenyi Biotec NeoGenomics ONCODE Scientific OncoDNA QIAGEN PANAGENE Personal Genome Diagnostics Predicin ScreenCell Tecan Thermo Fisher Scientific The geographical scope of the study covers Amoy Diagnostics, ArcherDX, Biocartis, Cell Search, CellMax Life , Datar Cancer Genetics, DiaCarta, EONE-DIAGNOMICS, Exosome Diagnostics, GeneCast Biotechnology, Integrated DNA Technologies, Lucence, MDNA Life Sciences, Miltenyi Biotec, NeoGenomics , ONCODE Scientific, OncoDNA, QIAGEN, PANAGENE, Personal Genome Diagnostics, Predicin, ScreenCell , Tecan, Thermo Fisher Scientific. Each region is examined with respect to current demand, accessibility of products, and regional developments. These geographic insights contribute to a deeper understanding of the global ‘Liquid Biopsy Market share and help identify performance differences between developed and emerging markets. The report features profiles of key players operating in the ‘Liquid Biopsy sector, including Amoy Diagnostics, ArcherDX, Biocartis, Cell Search, CellMax Life , Datar Cancer Genetics, DiaCarta, EONE-DIAGNOMICS, Exosome Diagnostics, GeneCast Biotechnology, Integrated DNA Technologies, Lucence, MDNA Life Sciences, Miltenyi Biotec, NeoGenomics , ONCODE Scientific, OncoDNA, QIAGEN, PANAGENE , Personal Genome Diagnostics, Predicin, ScreenCell , Tecan, Thermo Fisher Scientific. These company profiles provide a snapshot of their business strategy, market presence, and major contributions to the ‘Liquid Biopsy Market. The study further discusses market performance across various regions, product categories, and other segments. It presents a factual evaluation of the ‘Liquid Biopsy industry share and reviews the regulatory and operational dynamics influencing global adoption. The report emphasizes consistency and clarity in presenting the forecast model and expected market trajectory. Readers are also presented with analysis on corporate strategies including mergers and acquisitions, regional partnerships, and joint ventures. These strategies are reviewed in the context of historical data and current execution trends, offering an informed overview of ‘Liquid Biopsy Market growth potential. The report highlights the impact of external conditions such as pricing changes, investment flow, and emerging business models. It avoids speculation and focuses on available insights that can guide real-world business decisions. Coverage includes major areas of interest for companies exploring new opportunities in the market for ‘Liquid Biopsy. Research Methodology This study is backed by structured primary and secondary research methodologies. Roots Analysis used a range of reliable sources including company disclosures, government records, and expert interviews. The research framework supports accurate and transparent analysis, allowing businesses to derive actionable insights from the ‘Liquid Biopsy Market forecast. For more information or to request a personalized version of this report, please contact our team at sales@rootsanalysis.com. We are happy to support your specific business objectives with customized research solutions.